Novo Nordisk says Ozempic 2 mg had lower major CV event risk than Mounjaro
A real-world study cited by Novo Nordisk found adults with type 2 diabetes who escalated Ozempic to 2 mg from 1 mg had a lower risk of major cardiovascular events than those who switched to Eli Lilly’s Mounjaro.
COPENHAGEN, Sept 29 (Reuters) — Novo Nordisk said on Tuesday a real-world study found that adults with type 2 diabetes who increased their Ozempic dose to 2 milligrams (mg) from 1 mg had a lower risk of major cardiovascular events than patients who switched to Eli Lilly's Mounjaro. Reporting by Louise Rasmussen, editing by Stine Jacobsen. com; +45 21 27 97 79.